BMO Capital Maintains Outperform Rating for Immunogen: Here's What You Need To Know
Portfolio Pulse from Benzinga Insights
BMO Capital has maintained its Outperform rating for Immunogen (NASDAQ:IMGN) and raised its price target from $25.00 to $26.00. Despite this, shares of Immunogen are trading down 1.4% over the last 24 hours.
August 04, 2023 | 9:49 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
BMO Capital has maintained its Outperform rating for Immunogen and raised its price target. However, the stock is currently trading down.
While BMO Capital's maintained Outperform rating and increased price target for Immunogen are positive signals, the stock's current downward trend may offset these positive factors in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100